Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 |
| | 10-K | 10-K/A | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Xifaxan | | | | | | 117.9 | 79.9 | |
| Other—Anusol/Azasan/Diuril/Pepcid/Proctocort/Relistor | | | | | | 32.9 | | |
| Other | | | | | | 82.1 | 98.8 | |
| Total revenues [+] | 1,133.5 | 913.8 | 735.4 | 540.5 | 337.0 | 232.9 | 178.8 | 235.8 |
| Products | | | | | | | 178.8 | 232.9 |
| Revenue growth [+] | 24.0% | 24.2% | 36.1% | 60.4% | 44.7% | 30.3% | -24.2% | 13.1% |
| Xifaxan | | | | | | 47.6% | | |
| Cost of goods sold | 553.9 | 222.5 | 169.9 | 95.4 | 68.7 | 63.5 | 36.7 | 55.0 |
| Gross profit | 579.6 | 736.0 | 610.8 | 445.1 | 268.3 | 169.4 | 142.1 | 180.8 |
| Gross margin | 51.1% | 80.5% | 83.1% | 82.4% | 79.6% | 72.7% | 79.5% | 76.7% |
| Selling, general and administrative | 660.1 | 342.4 | 296.5 | 219.5 | 156.1 | 120.0 | 95.1 | 86.5 |
| Research and development | 170.3 | 112.8 | 85.0 | 71.9 | 73.3 | 89.5 | 83.7 | 73.8 |
| Other operating expenses | 77.0 | 28.5 | 15.8 | 37.9 | 10.4 | | 9.9 | 8.6 |
| EBITDA [+] | -101.5 | 304.4 | 265.8 | 131.1 | 41.8 | -25.6 | -33.7 | 22.5 |
| EBITDA growth | -133.3% | 14.5% | 102.7% | 213.7% | -263.2% | -24.0% | -249.8% | -38.9% |
| EBITDA margin | -9.0% | 33.3% | 36.1% | 24.3% | 12.4% | -11.0% | -18.8% | 9.5% |
| Depreciation | 10.2 | 7.4 | 6.8 | 4.3 | 2.9 | 3.0 | 13.0 | 10.6 |
| EBITA | -111.6 | 297.1 | 259.0 | 126.8 | 38.8 | -28.6 | -46.7 | 11.9 |
| EBITA margin | -9.8% | 32.5% | 35.2% | 23.5% | 11.5% | -12.3% | -26.1% | 5.0% |
| Amortization of intangibles | 216.1 | 44.7 | 45.4 | 10.9 | 10.4 | 11.5 | | |
| EBIT [+] | -327.8 | 252.3 | 213.7 | 115.9 | 28.5 | -40.1 | -46.7 | 11.9 |
| EBIT growth | -229.9% | 18.1% | 84.4% | 306.9% | -171.0% | -14.0% | -493.7% | -60.9% |
| EBIT margin | -28.9% | 27.6% | 29.1% | 21.4% | 8.5% | -17.2% | -26.1% | 5.0% |
| Non-recurring items [+] | 162.3 | | 41.6 | | 34.7 | | | |
| Asset impairment | 162.3 | | 41.6 | | 34.7 | | | |
| Interest expense, net [+] | 170.8 | 62.0 | 55.5 | 29.8 | 18.0 | 5.5 | 3.8 | |
| Interest expense | 170.8 | 62.0 | 55.5 | 32.1 | 20.7 | 6.7 | 3.8 | |
| Interest income | | 2.0 | 10.9 | 2.3 | 2.6 | 1.2 | | |
| Other income (expense), net [+] | -2.7 | 2.0 | -4.7 | | | | 2.7 | 3.3 |
| Gain (loss) on debt retirement | | | -15.6 | | | | | |
| Other | -2.7 | 2.0 | 10.9 | | | | | |
| Pre-tax income | -663.6 | 192.3 | 111.8 | 86.1 | -24.2 | -45.6 | -47.7 | 15.2 |
| Income taxes | -248.7 | 61.5 | 47.6 | -1.3 | 2.9 | -2.0 | -0.1 | 7.0 |
| Tax rate | 37.5% | 32.0% | 42.5% | | | 4.4% | 0.2% | 45.8% |
| Net income | -414.9 | 130.8 | 64.2 | 87.4 | -27.1 | -43.6 | -47.6 | 8.2 |
| Net margin | -36.6% | 14.3% | 8.7% | 16.2% | -8.0% | -18.7% | -26.6% | 3.5% |
| |
| Basic EPS [+] | ($6.53) | $2.12 | $1.09 | $1.49 | ($0.47) | ($0.88) | ($0.99) | $0.17 |
| Growth | -408.4% | 93.6% | -26.5% | -415.2% | -46.6% | -11.1% | -671.9% | -74.3% |
| Diluted EPS [+] | ($6.53) | $1.99 | $1.01 | $1.33 | ($0.47) | ($0.88) | ($0.99) | $0.17 |
| Growth | -427.9% | 97.4% | -24.4% | -382.6% | -46.6% | -11.1% | -688.2% | -74.1% |
| |
| Shares outstanding (basic) [+] | 63.5 | 61.8 | 58.7 | 58.7 | 57.3 | 49.4 | 47.9 | 47.3 |
| Growth | 2.8% | 5.2% | 0.0% | 2.5% | 16.1% | 3.0% | 1.2% | 1.5% |
| Shares outstanding (diluted) [+] | 63.5 | 65.7 | 63.7 | 65.5 | 57.3 | 49.4 | 47.9 | 48.7 |
| Growth | -3.3% | 3.1% | -2.7% | 14.3% | 16.1% | 3.0% | -1.6% | 0.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|